Liminatus Pharma, Inc. (LIMN) Form 10-Q — Aug 14, 2026
Liminatus Pharma's 10-Q for the quarter ended June 30, 2026 carries an explicit going-concern warning: management concluded there is substantial doubt about the company's ability to continue operations, with just $3.0 million in cash against a $2.5 million net loss for the first half of 2026 and a $41.4 million accumulated deficit. The company is fighting to keep its Nasdaq listing.
Key figures
- Total Debt
- 1442500
- Cash Position
- 3017096
- Offering Price
- 0.29
- Shares Outstanding
- 67160362
- Q2 2026 net loss
- 1407259
- H1 2026 ga expense
- 1479806
- H1 2026 rd expense
- 1000000
- Accumulated deficit
- 41402706
- Nasdaq mvls minimum
- 50000000
- Nasdaq mvphs minimum
- 15000000
- Feb2026 shares offered
- 8270000
- Feb2026 common warrants
- 20719500
- Series a conversion ratio
- each preferred share convertible into 10,000 common shares
- Feb2026 prefunded warrants
- 5543000
- Inducement warrants issued
- 20688000
- H1 2026 loss from operations
- 2479806
- Clear street settlement value
- 7360000
- Feb2026 offering net proceeds
- 3444427
- Innocsai common shares issued
- 11188729
- Reverse split authorized ratio
- up to 1-for-50
- Shares outstanding dec 31 2025
- 27064633
- Shares outstanding jun 30 2026
- 55971633
- Unpaid deferred underwriting fee
- 500000
- Nasdaq bid price compliance deadline
- September 3, 2026
- Innocsai original consideration shares
- 1600000000
- June2026 warrant inducement net proceeds
- 1622967
- Innocsai original issuance price per share
- 0.2
- June2026 warrant inducement gross proceeds
- 1861921
Price after filing
1 day: +4900.0%7 days: +3585.7%30 days: +2378.6%
Close on the filing date to close N calendar days later (from $0.14). Historical, not a forecast.
AI analysis
Red flags10 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.